EMYRIA LIMITED - News & Media

6.52%

4.9¢

Market Cap $29.96M

Healthcare Biotechnology

Emyria Limited is an Australia-based early-stage drug development company. The Company is... Emyria Limited is an Australia-based early-stage drug development company. The Company is focused on delivering and developing treatments for mental health and select neurological conditions, guided by real-world data collected with patients across its wholly owned clinical service subsidiaries. Its pipeline comprises MDMA analogue drug development and commercialization of novel serotonin-releasing agents. Its Emyria Healthcare provides evidence-based treatment for patients not finding relief from conventional care, while also helping evaluate emerging new therapies like assisted therapy for post-traumatic stress disorder (PTSD) and assisted therapy for treatment-resistant depression. Its Emyria Data is a robust and ethically sourced real-world data gathered with patients and used to improve its therapy and drug development programs. Its Emyria’s Pipeline includes new psychedelic-assisted therapies and drug treatments for mental health and select neurological diseases.More

HELPING PATIENTS ON THEIR JOURNEY TO BETTER HEALTH

Little Green Pharma (ASX:LGP) to benefit as Denmark commits to cannabis pilot program.

Articles & Videos

Emyria Advances kicks off National Rollout with Avive Health Agreement

Clinical-stage biotech and mental health innovator Emyria Limited (ASX:EMD) has fired up its national expansion strategy by signing a landmark agreement with Avive Health, a growing private hospital operator, to establish its first Empax clinic in Queensland.Under the agreement, Emyria will integ...

2 days ago

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 4.9¢		Change 0.003(6.52%)		Mkt cap ! $29.96M

Open	High	Low	Value	Volume
4.7¢	5.1¢	4.6¢	$419.0K	8.556M

Buyers (Bids)

No.	Vol.	Price($)
1	26714	4.9¢

Sellers (Offers)

Price($)	Vol.	No.
5.0¢	180000	3

View Market Depth

No.	Vol.	Price($)
1	26714	0.049
1	4166	0.048
4	362367	0.047
5	331739	0.046
8	371234	0.045

Price($)	Vol.	No.
0.050	180000	3
0.051	100000	2
0.052	202777	3
0.053	36861	2
0.054	24000	1

Last trade - 16.10pm 31/07/2025 (20 minute delay)


Last 4.9¢		Change 0.003 ( 6.52 %)
Open	High	Low	Volume
4.7¢	5.0¢	4.6¢	2343943
Last updated 15.57pm 31/07/2025 ?

EMD (ASX) Chart

EMYRIA LIMITED - News & Media

Articles & Videos

Emyria Advances kicks off National Rollout with Avive Health Agreement

Emyria opens second Empax centre in Perth to meet mental health demand

Emyria to plug $2.5M into depression treatment program at Empax Centre

Emyria, UWA seek commercialisation of compounds to treat PTSD and Parkinson's

Emyria jumps 10% on 'interim' success treating PTSD patients with MDMA

Emyria and UWA secure $499,411 grant to advance MDMA analogue drug program

Emyria's Empax Centre chosen for mental health clinical trial

Emyria locks in $2.3M to progress MDMA research – with Chair adding $0.3M

Emyria launches Empax Centre - pioneering innovation in mental health treatment

Emyria hits milestone in PTSD treatment with first female specialist for MDMA therapy

Buyers (Bids)

Sellers (Offers)

Infini Resources appoints Rohan Bone as CEO ahead of Phase 2 campaign

Resolution Minerals appoints industry experts to fast-track US growth strategy

A new NASDAQ listing for a key player in the global critical minerals space

Top Stories